BIOTE CORP -A (BTMD) Stock Fundamental Analysis

NASDAQ:BTMD • US0906831039

2.08 USD
-0.02 (-0.95%)
Last: Mar 3, 2026, 02:11 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Taking everything into account, BTMD scores 5 out of 10 in our fundamental rating. BTMD was compared to 193 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of BTMD get a neutral evaluation. Nothing too spectacular is happening here. BTMD is valued quite cheap, while showing a decent growth score. This is a good combination!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year BTMD was profitable.
  • BTMD had a positive operating cash flow in the past year.
  • Of the past 5 years BTMD 4 years were profitable.
  • Of the past 5 years BTMD 4 years had a positive operating cash flow.
BTMD Yearly Net Income VS EBIT VS OCF VS FCFBTMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

1.2 Ratios

  • BTMD has a better Return On Assets (25.87%) than 98.45% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 45.22%, BTMD belongs to the top of the industry, outperforming 99.48% of the companies in the same industry.
Industry RankSector Rank
ROA 25.87%
ROE N/A
ROIC 45.22%
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BTMD Yearly ROA, ROE, ROICBTMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 400 600

1.3 Margins

  • Looking at the Profit Margin, with a value of 14.72%, BTMD belongs to the top of the industry, outperforming 87.05% of the companies in the same industry.
  • BTMD's Profit Margin has declined in the last couple of years.
  • The Operating Margin of BTMD (16.09%) is better than 86.53% of its industry peers.
  • BTMD's Operating Margin has declined in the last couple of years.
  • With a decent Gross Margin value of 72.23%, BTMD is doing good in the industry, outperforming 79.27% of the companies in the same industry.
  • In the last couple of years the Gross Margin of BTMD has grown nicely.
Industry RankSector Rank
OM 16.09%
PM (TTM) 14.72%
GM 72.23%
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
BTMD Yearly Profit, Operating, Gross MarginsBTMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BTMD is creating value.
  • The number of shares outstanding for BTMD has been reduced compared to 1 year ago.
  • BTMD has a worse debt/assets ratio than last year.
BTMD Yearly Shares OutstandingBTMD Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
BTMD Yearly Total Debt VS Total AssetsBTMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 2.21 indicates that BTMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • BTMD has a better Altman-Z score (2.21) than 63.73% of its industry peers.
  • The Debt to FCF ratio of BTMD is 4.18, which is a neutral value as it means it would take BTMD, 4.18 years of fcf income to pay off all of its debts.
  • BTMD's Debt to FCF ratio of 4.18 is amongst the best of the industry. BTMD outperforms 86.01% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.18
Altman-Z 2.21
ROIC/WACC4.92
WACC9.19%
BTMD Yearly LT Debt VS Equity VS FCFBTMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

  • BTMD has a Current Ratio of 1.01. This is a normal value and indicates that BTMD is financially healthy and should not expect problems in meeting its short term obligations.
  • BTMD has a worse Current ratio (1.01) than 83.42% of its industry peers.
  • BTMD has a Quick Ratio of 1.01. This is a bad value and indicates that BTMD is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.72, BTMD is doing worse than 83.94% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 0.72
BTMD Yearly Current Assets VS Current LiabilitesBTMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • BTMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 190.00%, which is quite impressive.
  • Measured over the past years, BTMD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -48.53% on average per year.
  • Looking at the last year, BTMD shows a very negative growth in Revenue. The Revenue has decreased by -18.44% in the last year.
  • The Revenue has been growing by 12.38% on average over the past years. This is quite good.
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
Revenue 1Y (TTM)-18.44%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%

3.2 Future

  • Based on estimates for the next years, BTMD will show a very strong growth in Earnings Per Share. The EPS will grow by 41.42% on average per year.
  • The Revenue is expected to grow by 6.89% on average over the next years.
EPS Next Y229.18%
EPS Next 2Y7.66%
EPS Next 3Y9.09%
EPS Next 5Y41.42%
Revenue Next Year-3.44%
Revenue Next 2Y-0.58%
Revenue Next 3Y2.36%
Revenue Next 5Y6.89%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BTMD Yearly Revenue VS EstimatesBTMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
BTMD Yearly EPS VS EstimatesBTMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 2.39, the valuation of BTMD can be described as very cheap.
  • BTMD's Price/Earnings ratio is rather cheap when compared to the industry. BTMD is cheaper than 98.45% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of BTMD to the average of the S&P500 Index (27.13), we can say BTMD is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 8.16, the valuation of BTMD can be described as very reasonable.
  • Based on the Price/Forward Earnings ratio, BTMD is valued cheaper than 92.23% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.11. BTMD is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 2.39
Fwd PE 8.16
BTMD Price Earnings VS Forward Price EarningsBTMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 96.37% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, BTMD is valued cheaper than 98.96% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.76
EV/EBITDA 5.99
BTMD Per share dataBTMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • BTMD has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y7.66%
EPS Next 3Y9.09%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BTMD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOTE CORP -A

NASDAQ:BTMD (3/3/2026, 2:11:49 PM)

2.08

-0.02 (-0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05
Earnings (Next)03-11
Inst Owners63.14%
Inst Owner Change0.4%
Ins Owners10.06%
Ins Owner Change0%
Market Cap94.97M
Revenue(TTM)195.65M
Net Income(TTM)28.79M
Analysts81.82
Price Target4.94 (137.5%)
Short Float %5.72%
Short Ratio10.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)270.4%
Min EPS beat(2)178.65%
Max EPS beat(2)362.15%
EPS beat(4)3
Avg EPS beat(4)249.23%
Min EPS beat(4)-1.96%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)105.05%
EPS beat(12)7
Avg EPS beat(12)16.44%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.43%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)-1.55%
Revenue beat(4)1
Avg Revenue beat(4)-1.97%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.65%
Revenue beat(12)4
Avg Revenue beat(12)-1.32%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.08%
EPS NY rev (1m)0%
EPS NY rev (3m)23.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.52%
Valuation
Industry RankSector Rank
PE 2.39
Fwd PE 8.16
P/S 0.49
P/FCF 2.76
P/OCF 2.37
P/B N/A
P/tB N/A
EV/EBITDA 5.99
EPS(TTM)0.87
EY41.83%
EPS(NY)0.26
Fwd EY12.26%
FCF(TTM)0.75
FCFY36.23%
OCF(TTM)0.88
OCFY42.11%
SpS4.28
BVpS-1.59
TBVpS-1.9
PEG (NY)0.01
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 25.87%
ROE N/A
ROCE 57.24%
ROIC 45.22%
ROICexc 92.24%
ROICexgc 190.38%
OM 16.09%
PM (TTM) 14.72%
GM 72.23%
FCFM 17.59%
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-32.05%
ROICexgc growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score7
Asset Turnover1.76
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.18
Debt/EBITDA 3.02
Cap/Depr 144.67%
Cap/Sales 2.85%
Interest Coverage 3.81
Cash Conversion 113.15%
Profit Quality 119.51%
Current Ratio 1.01
Quick Ratio 0.72
Altman-Z 2.21
F-Score7
WACC9.19%
ROIC/WACC4.92
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
EPS Next Y229.18%
EPS Next 2Y7.66%
EPS Next 3Y9.09%
EPS Next 5Y41.42%
Revenue 1Y (TTM)-18.44%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%
Revenue Next Year-3.44%
Revenue Next 2Y-0.58%
Revenue Next 3Y2.36%
Revenue Next 5Y6.89%
EBIT growth 1Y-29.68%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year30.98%
EBIT Next 3Y13.56%
EBIT Next 5Y13.39%
FCF growth 1Y43.63%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y53.94%
OCF growth 3Y10.29%
OCF growth 5Y12.28%

BIOTE CORP -A / BTMD FAQ

Can you provide the ChartMill fundamental rating for BIOTE CORP -A?

ChartMill assigns a fundamental rating of 5 / 10 to BTMD.


Can you provide the valuation status for BIOTE CORP -A?

ChartMill assigns a valuation rating of 9 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.


Can you provide the profitability details for BIOTE CORP -A?

BIOTE CORP -A (BTMD) has a profitability rating of 6 / 10.


How financially healthy is BIOTE CORP -A?

The financial health rating of BIOTE CORP -A (BTMD) is 4 / 10.


How sustainable is the dividend of BIOTE CORP -A (BTMD) stock?

The dividend rating of BIOTE CORP -A (BTMD) is 0 / 10 and the dividend payout ratio is 0%.